NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of “Moderate Buy” from Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $38.25.

A number of equities research analysts have weighed in on NRXP shares. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Finally, BTIG Research reiterated a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th.

NRx Pharmaceuticals Trading Up 2.2%

NRXP stock opened at $4.14 on Monday. The stock has a market capitalization of $149.99 million, a PE ratio of -3.80 and a beta of 2.14. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The stock’s 50 day simple moving average is $3.01 and its 200 day simple moving average is $2.43.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $19.43 million. On average, research analysts predict that NRx Pharmaceuticals will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sjbenen Advisory LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth $41,000. Ethos Financial Group LLC increased its stake in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 35.3% in the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth $107,000. Finally, Two Sigma Investments LP increased its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.